UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals (VNDA.O) in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach condition drug in September.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,